Skip to content

Study · Not a test of the peptide alone · 2023

5 results

An SS31-rapamycin conjugate via RBC hitchhiking for reversing acute kidney injury.

Yu B, Liu Y, Zhang Y, Xu L, Jin K, Sun A, Zhao X, Wang Y, Liu H

Biomaterials2 Nov 2023Cited by 12 (Europe PMC)

PMID37939640 (opens in a new tab)DOI10.1016/j.biomaterials.2023.122383 (opens in a new tab)PepBankPUB-37939640
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    The SS31-rapamycin conjugate carried by red blood cell hitchhiking prolonged the half-life of SS31 by 6.9 folds.

    In plain wordsCarrying the SS31-rapamycin conjugate inside red blood cells made SS31 stay in the body 6.9 times longer.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSS31 half-life with RBC hitchhiking
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Half-life prolongation of SS31
    6.9 fold
    RBC hitchhiking

    Source sentences

    Summary
    The new RBC hitchhiking strategy enables the encapsulation of conjugate into RBC via a less traumatic and more natural and permissive manner, resulting in prolonging the t1/2 of SS31 by 6.9 folds.
    1 context sentence
    Summary · context
    Herein, we conjugated SS31, a mitochondria-targeted antioxidant tetrapeptide connecting a cleavable linker to rapamycin (Rapa), which provided specific interaction with FK506-binding protein (FKBP) in the RBCs.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    A single dose of SS31-rapamycin reversed cisplatin-induced acute kidney injury.

    In plain wordsIn this study, a single dose of the SS31-rapamycin conjugate reversed kidney injury caused by cisplatin.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCisplatin-induced acute kidney injury
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Combined with autophagy induction associated with Rapa, a single dose of SS31-Rapa can effectively reverse cisplatin and ischemia reperfusion-induced AKI.
    1 context sentence
    Summary · context
    Herein, we conjugated SS31, a mitochondria-targeted antioxidant tetrapeptide connecting a cleavable linker to rapamycin (Rapa), which provided specific interaction with FK506-binding protein (FKBP) in the RBCs.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    A single dose of SS31-rapamycin reversed ischemia reperfusion-induced acute kidney injury.

    In plain wordsIn this study, a single dose of the SS31-rapamycin conjugate reversed kidney injury caused by blocked blood flow.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseIschemia reperfusion-induced acute kidney injury
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Combined with autophagy induction associated with Rapa, a single dose of SS31-Rapa can effectively reverse cisplatin and ischemia reperfusion-induced AKI.
    1 context sentence
    Summary · context
    Herein, we conjugated SS31, a mitochondria-targeted antioxidant tetrapeptide connecting a cleavable linker to rapamycin (Rapa), which provided specific interaction with FK506-binding protein (FKBP) in the RBCs.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    SS31-rapamycin underwent direct cellular uptake instead of the lysosomal pathway.

    In plain wordsIn cells, the SS31-rapamycin conjugate entered directly and not through the lysosome.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableCellular uptake pathway
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    SS31-Rapa underwent the direct cellular uptake, instead of the lysosomal pathway
    1 context sentence
    Summary · context
    Herein, we conjugated SS31, a mitochondria-targeted antioxidant tetrapeptide connecting a cleavable linker to rapamycin (Rapa), which provided specific interaction with FK506-binding protein (FKBP) in the RBCs.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In apoptotic cells, SS31-rapamycin released SS31 in response to activated caspase-3, favouring mitochondrial accumulation of SS31.

    In plain wordsIn dying cells, the conjugate released SS31, which then collected in mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSS31 release and mitochondrial accumulation
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Pharmacology

    Source sentences

    Summary
    released SS31 in response to activated caspase-3 stimulation in apoptotic cells, favoring the mitochondrial accumulation of SS31.
    1 context sentence
    Summary · context
    Herein, we conjugated SS31, a mitochondria-targeted antioxidant tetrapeptide connecting a cleavable linker to rapamycin (Rapa), which provided specific interaction with FK506-binding protein (FKBP) in the RBCs.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.